Exchange Traded Concepts LLC boosted its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 6.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,383 shares of the company’s stock after purchasing an additional 474 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Zoetis were worth $1,307,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Nova Wealth Management Inc. bought a new position in Zoetis in the first quarter worth $25,000. 1248 Management LLC bought a new position in shares of Zoetis during the first quarter valued at $27,000. Saudi Central Bank bought a new position in shares of Zoetis during the first quarter valued at $29,000. Cornerstone Planning Group LLC increased its holdings in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock valued at $42,000 after acquiring an additional 120 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Zoetis Trading Down 0.8%
Shares of NYSE:ZTS opened at $144.73 on Tuesday. The stock has a market capitalization of $64.14 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 2.34 and a beta of 0.88. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock’s 50-day simple moving average is $151.03 and its two-hundred day simple moving average is $156.27. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $197.51.
Analysts Set New Price Targets
Several brokerages have recently weighed in on ZTS. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and reduced their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $200.88.
Get Our Latest Report on Zoetis
About Zoetis
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Read More
- Five stocks we like better than Zoetis
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- How The Weak Dollar Is Fueling These Global Stock Surges
- Consumer Discretionary Stocks Explained
- 3 Recession-Ready Stocks That Thrive When the Economy Sputters
- Best Stocks Under $10.00
- 3 Automation-Focused Stocks Flying Under the Radar
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.